Surgery Partners shares edge lower despite Q2 revenue beat
Surgery Partners (NASDAQ:SGRY) shares fell 0.71% pre-market after Q2 results were mixed. Revenue rose to $848.9M, above the $830.05M forecast, and same-facility revenue grew 5%. Adjusted EPS was $0.10 vs $0.06 consensus, but GAAP net loss was $0.12/share. Adjusted EBITDA fell to $125.2M. Company reaffirmed 2026 revenue $3.35B-$3.45B and adjusted EBITDA at least $530M.
How this was made
The 30-second read
Why it matters
Traders likely reprice the stock on the combination of a revenue beat and weaker profitability and cash flow, while monitoring leverage (net debt-to-EBITDA ~4.4x) and the effect of the pending facility divestiture.
Market read
A revenue beat with falling adjusted EBITDA and operating cash flow, plus reaffirmed 2026 guidance, creates a mixed setup for near-term positioning.
What to watch
The guidance excludes the pending Idaho Falls facility divestiture, so investors may be underweighting how asset sales could affect future EBITDA and cash flow optics.
Background
Surgery Partners is a healthcare services operator reporting quarterly results with same-facility metrics and full-year guidance.
Ticker impact
Surgery Partners reported Q2 revenue of $848.9M above estimates but adjusted EBITDA fell to $125.2M, and operating cash flow dropped to $59.3M.
Near-term downside bias versus revenue-only bulls, with focus on leverage and cash flow trajectory despite guidance hold.
The article’s incremental decision inputs are the Q2 EPS/EBITDA/cash flow prints and the reaffirmed 2026 revenue and adjusted EBITDA floor, which together suggest growth without near-term margin or cash conversion improvement.
Market effects
Highlights ongoing margin and cash-flow pressure risk in healthcare services even when same-facility revenue trends improve.
None indicated.
None indicated.
Counterpoint
The same-facility revenue growth and revenue-per-case rise could translate into margin recovery later, making the EBITDA decline more temporary than structural.
Key entities
- companySurgery Partners, Inc.
NASDAQ-listed healthcare services company reporting Q2 results and reaffirming 2026 guidance.
- personEric Evans
CEO quoted on progress toward strategic priorities and the short stay surgical platform.
